Intermediate-Term Efficacy and Tolerance of Statins in Children
| Autor: | Nathalie Mamann, A. Karsenty, Julie Lemale, Jean-Philippe Girardet, Patrick Tounian, Béatrice Dubern |
|---|---|
| Přispěvatelé: | Service de nutrition et gastroentérologie pédiatriques [CHU Trousseau], CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU) |
| Rok vydání: | 2019 |
| Předmět: |
Male
medicine.medical_specialty Adolescent [SDV]Life Sciences [q-bio] Pain Familial hypercholesterolemia Lipid-lowering therapy Hyperlipoproteinemia Type II 03 medical and health sciences 0302 clinical medicine Dysuria 030225 pediatrics Internal medicine Low density Humans Medicine Prospective Studies 030212 general & internal medicine Child Creatine Kinase Intermediate term business.industry nutritional and metabolic diseases Cholesterol LDL Myalgia medicine.disease Abdominal Pain 3. Good health Large cohort Tolerability Pediatrics Perinatology and Child Health Female lipids (amino acids peptides and proteins) Statin therapy Hydroxymethylglutaryl-CoA Reductase Inhibitors business |
| Zdroj: | Journal of Pediatrics Journal of Pediatrics, Elsevier, 2019, 210, pp.161-165. ⟨10.1016/j.jpeds.2019.03.032⟩ |
| ISSN: | 0022-3476 |
| DOI: | 10.1016/j.jpeds.2019.03.032 |
| Popis: | To evaluate the intermediate-term efficacy and tolerance of statins in children and adolescents with familial hypercholesterolemia.A total of 131 children or adolescents treated with statins for familial hypercholesterolemia were prospectively included. The efficacy of treatment was established by the percentage of children who achieved low density lipoprotein-cholesterol (LDL-C) levels160 mg/dL during treatment. Treatment tolerance was evaluated by the occurrence of clinical or laboratory side effects, regularity of increases in height and weight, and pubertal development.The median duration of treatment with statins was 4 years. A median decrease of 32% in LDL-C levels was observed (P .0001). The therapeutic target (LDL-C160 mg/dL) was achieved in 67% of cases. Increases in height and weight and sexual maturation were not affected by the treatment. Minor side effects were reported for 24 (18.4%) patients including 3 cases of a clinically asymptomatic increase in creatine phosphokinase (CPK) levels, 2 cases of an increase in CPK levels with muscular symptoms, 14 cases of myalgia without an increase in CPK levels, 3 cases of abdominal pain, 1 case of dysuria, and 1 case of diffuse pain. None of these side effects led to the discontinuation of statin therapy, although a change of statin was required in 7 cases. This new statin was tolerated in all cases. No patients had abnormal liver function during treatment.The results of this large cohort confirm the intermediate-term safety and efficacy of statin therapy in children with familial hypercholesterolemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect